Cytos Biotechnology AG

EQS-Adhoc: Cytos Biotechnology AG: Extension of convertible bond listing at SIX Swiss Exchange

EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Bond
Cytos Biotechnology AG: Extension of convertible bond listing at SIX
Swiss Exchange

13.04.2015 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------

Extension of convertible bond listing at SIX Swiss Exchange

Schlieren (Zurich), Switzerland, April 13, 2015 - Cytos Biotechnology Ltd
("Cytos") today announced that, the last day of trading of the convertible
bond at the SIX Swiss Exchange was moved to April 30, 2015. According to
the Court the 30 day appeal period related to the bond restructuring was
interrupted due to Easter break and therefore has to be formally extended
to the end of April.

The final approval of the restructuring by the superior composition
authority of creditors of the canton of Zurich ("Obere Kantonale
Nachlassbehörde") is expected for the beginning of May 2015, followed by
the conversion of the convertible bonds into equity.

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words "will" or "expect" or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, Against the
background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
developments.

www.cytos.com
End of ad hoc announcement

+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=JHGGTTLRXU
Document title: Cytos_Extension_150413

---------------------------------------------------------------------

13.04.2015 News transmitted by EQS Schweiz AG. www.eqs.com - news
archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

---------------------------------------------------------------------


Language:    English
Company:     Cytos Biotechnology AG
             Wagistr. 25
             8952 Schlieren
             Switzerland
Phone:       +41 44 733 4747
Fax:         +41 44 733 4740
E-mail:   info@cytos.com
Internet: www.cytos.com
ISIN:        CH0011025217, CH0029060735
Valor:       -
Listed:      Regulated Unofficial Market in Berlin, Munich, Stuttgart;
             Open Market in Frankfurt ; SIX


End of News    EQS Group News-Service
---------------------------------------------------------------------
343207 13.04.2015
 



Weitere Meldungen: Cytos Biotechnology AG

Das könnte Sie auch interessieren: